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INTRODUCTION 
Antimicrobials are used in animals to treat bacterial 
infections causing identifiable clinical syndromes which 
cause pain and suffering and which can result in death 
or chronic disease, and for growth promotion or 
improvement in productivity. The animal populations 
in which they are used fall into two groups: the 
companion animals, which have population structures 
similar to those of man, with relatively small numbers 
of young animals, individual housing, a high standard 
of individual veterinary attention not dependent on 
economics and the possibility that sick individuals can 
be nursed; and food animals which are generally young, 
are kept in large groups and become uneconomic if ill 
for any length of time. The way in which antimicrobials 
are used in these two populations differs fundamentally 
and the risks to human health also differ, although not 
to such a great extent. It is helpful to understand the 
ways in which antimicrobials are used in both groups 
and to examine the risk to human health of each type 
of practice. 
Food animal populations and medication 
Food animals include animals such as cattle, sheep, 
pigs, rabbits, chickens, turkeys, ducks, ostriches, quail, 
pheasant, trout, salmon and other farmed fish such as 
sea bass. All of these species exist as adults intended to 
provide the slaughter generation and required to 
reproduce for maximum eaciency, and the slaughter 
generation itself which must grow rapidly to the size 
appropriate for marketing, usually before sexual 
maturity and always before physical maturity. These 
animals are kept in groups (they are all social species) 
and are often housed for all or part of their rearing 
process to protect them from climatic extremes. There 
are two exceptions to this general rule, the dairy cow, 
which produces milk for sale, and the laying hen. 
Populations of both these groups are adults in their 
productive phase, but both must remain at peak 
productivity to be retained in the herd or flock. The 
youth of the animals and their housing in groups means 
that infectious disease can spread rapidly in non- 
immune animals, as hygiene can be poor and as 
common airspaces lead to the spread of respiratory 
disease. Facilities and the capacity for nursing are 
limited, and individual treatment is often difficult or 
stressful. Treatment of groups of animals as soon as one 
member develops disease is essential if infection is to be 
eliminated from the group, and groups may be treated 
after infection and before clinical signs develop. 
An example of treatment at the onset of disease 
comes from poultry husbandry where E. coli septi- 
caemia may develop in a group of25000 birds at  10-14 
days of age. If untreated, 10% (2500) may die within 
seven days and another 10% may remain chronically 
affected and be unsuitable for slaughter at six to seven 
weeks of age. As the sick birds cannot be identified, 
treated individually in those numbers or isolated within 
the same poultry site (the infection spreads by the 
respiratory route), treatment of the group by medi- 
cating food or, particularly, the water is essential. There 
is no vaccine and prevention by hygiene and manage- 
ment does not always work. 
An example of treatment of a group of animals 
when infection is expected comes from pig husbandry 
where oedema disease occurs. This disease is caused by 
verotoxigenic E. coli and occurs within seven to ten 
days of weaning or dietary change in genetically 
suceptible pigs and cannot be treated once the toxin has 
been absorbed. Mortality rates reach 30% in successive 
batches of pigs as they are weaned and outbreaks may 
continue for months. Antibiotic treatment in food or 
water from weaning for seven to ten days completely 
prevents the disease [l]. Vaccine is not yet available, 
although egg yolk antibody, fimbrial vaccines and 
recombinant verotoxoids have all been shown to be 
protective in experiments. 
The economics of food animal production are 
currently poor in Europe, and particularly so in the UK 
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where some species are currently being produced at a 
loss. Disease and its associated costs are therefore to be 
avoided if at all possible but, if disease does occur, the 
keeper of the animals must safeguard animal welfare or 
face prosecution under the animal welfare legislation. 
I t  is against this background that the use of anti- 
microbials in food animals should be considered. 
Antimicrobials in food animals: regulation and residues 
Antimicrobials used in food animals fall into two 
groups: those used for therapy which can only be 
supplied and used on veterinary prescription, and those 
used for growth promotion which are freely available 
for that purpose from registered suppliers. All have 
been registered for these uses and are subject to the 
same general registration process and regulations 
governing their use throughout Europe. AU have been 
shown to be effective by means of controlled experi- 
ments in the target species, to be safe in the target 
species, and safe handling procedures have been devised 
to minimize risks to those involved in their supply and 
administration. Unused antimicrobial must be disposed 
of as pharmaceutical waste by approved routes. Safety 
for man has been addressed and the risk of residues in 
the carcase has been assessed prior to licensing, and a 
withdrawal period has been specified between the last 
treatment and slaughter, which must be observed. 
Monitoring for the effectiveness of this procedure takes 
place and it is clear that residues of antimicrobial in food 
of animal origin (meat, milk and eggs) are rare and do 
not pose a health hazard for man [2]. 
Benefits to human health from the use of antimicrobials in 
food animals 
One benefit is economic, linked to the price and quality 
of the food reaching the processor and eventually the 
public, and the other is reduction in numbers of 
zoonotic bacteria reaching man in food. The economic 
argument for the benefits of antimicrobial use in 
animals to human health is quite clear. Antimicrobial 
treatment of infectious disease has contributed markedly 
to the modern developments in animal husbandry 
which have delivered cheap and available animal protein 
to Western Europe and other developed parts of the 
world. They still contribute to traditional systems 
where animals are not kept in sophisticated buildings, 
but are less important where investment in housing, 
health status of stock and good management have 
occurred. The prompt treatment of disease has led to 
reductions in mortality, quicker return to health and 
productivity, and a reduction in valueless chronically- 
affected survivors of bacterial disease. 
A clear example of this comes from milk pro- 
duction, where most mastitis in milking cows is caused 
by infection with a limited number of organisms: 
Staphylococcus aureus, Streptococcus agalactiae, S. dysgalactiae, 
S. uberis and E. coli. Acute mastitis caused by these 
organisms can be treated and treatment generally results 
(with significant nursing support in E. coli mastitis) in 
the rapid reduction in pain and suffering, return of the 
gland to normal function (both yield and quality of 
milk return to normal), and a reduction in chronic 
damage to the affected mammary gland with a cure rate 
of 81% for a course of treatment [3]. The lifetime yield 
of milk from the cow is not reduced significantly and 
more milk is produced per cow than would be the case 
if the disease were allowed to continue unchecked. In 
modern mastitis control, treatment is only a part of the 
whole programme, but it is vital. Similar economic 
advantages accrue from the prompt treatment of 
postweaning E. coli diarrhoea in pigs. This condition 
results from the withdrawal of milk protective antibody 
at weaning and the exposure of the susceptible animal 
to infection from littermates or imperfectly-cleaned 
accommodation. Disease occurs within three days of 
weaning and may kill up to 30% of affected groups, 
leaving other animals permanently stunted. It is possible 
to reduce the severity of this condition in a number of 
ways, but even in the best possible conditions, mortality 
can still reach 5% if antimicrobial treatment is not given. 
Prompt and effective treatment with antimicrobial, 
coupled with nursing (maintenance of temperature, oral 
rehydration therapy), can reduce mortality to zero and 
allow growth to continue unchecked, thus reducing 
losses and allowing more margin over feed and fixed 
Antimicrobial used for growth promotion provides 
another example of the economic advantages of the use 
of antimicrobials. Regardless of the political discussion 
surrounding the use of antimicrobials as growth pro- 
moters, there are some technical facts that are beyond 
dispute. They are intended for use in clinically-normal 
animals and have no effect on the major bacterial 
diseases of livestock (if they had, they would have to be 
re-registered as therapeutics). They act by lulling or 
disabling bacteria in the gut of animals [4,5], thus 
reducing the damage caused by the normal flora to the 
intestinal villi through loss of tissue and inflammation 
and improving absorption through the now healthy villi. 
The effects of antimicrobial growth promoters on the 
gut of young growing animals can be seen clearly by 
comparing the histological appearance of the intestines 
of those receiving antimicrobial with those of control 
clinically-normal animals. The villi of animals receiving 
antimicrobial growth promoters are longer with more 
mature epithelial cells and fewer inflammatory cells. 
The lamina propria of the intestinal mucosa contains 
fewer plasma cells and lymphocytes, and fewer bacteria 
costs [l]. 
Notes and Comments 1 2 1  
of species such as enterococci and lactobacilli appear to 
be attached to the epithelium in the small intestine. 
Antimicrobial growth promoters also prevent bacterial 
degradation of food before it reaches the host and 
prevent the destruction of digestive enzymes by bacteria 
of the normal flora. The growth which results is a 
consequence of the improvement of gut function and is 
an indicator of health in normal immature animals. No 
animal receiving an antimicrobial growth promoter can 
grow beyond its genetic potential. The use of anti- 
microbial growth promoters therefore improves the 
physical welfare of the animals receiving them, as they 
are better nourished. Improvements of 5-10% in growth 
rate and feed efficiency are commonplace, resulting in 
a significant reduction in the cost of rearing food 
animals. The effects are absent in gnotobiotic animals, 
and are reduced in the presence of clinical hsease or 
adverse nutritional or environmental conditions. 
Benefits from a reduction in zoonotic pathogens 
are less clear cut, but are most clearly seen in salmonel- 
losis in calves. Calves with salmonellosis pass large 
volumes of diarrheic feces containing up to lo9 
organisms per gram for several days during the course 
of the disease. The  organisms have the potential to 
infect other calves, handlers, and cattle and other live- 
stock about to be sent to slaughter. Prompt treatment 
results in immediate reduction in the diarrhea and in 
the numbers of salmonellae discharged. Coupled with 
isolation, disinfection and management, the exposure 
of man to these organisms by all routes is reduced. 
Hazards to man of antimicrobial use in food animals 
There are two major areas of risk, one of direct 
exposure to antimicrobial while administering treat- 
ment or incorporating antimicrobial in animal feeds, 
and the other from antimicrobial resistance in zoonotic 
pathogens encountered in the workplace, or in food or 
following the transfer of resistance from normal animal 
flora in the workplace, or on food to human normal 
flora or pathogens. 
Direct exposure to antimicrobial 
Those working with antimicrobial (veterinarians, 
workers in feed mills, animal handlers) will be exposed 
to small amounts of the substances in dust or following 
accidents of administration. It is possible that toxicity 
may result, but antimicrobials are inherently safe from 
&rect toxicity and would not be licensed if they were 
toxic. Precautions to avoid contamination are laid down 
in the data sheets [6] and in safety assessments. Allergy 
is more difficult to prevent and remains a possibility for 
those handling animal medicines. In addition the 
antimicrobial being used may be ingested and may 
affect the flora of the worker. 
Antimicrobial resistance 
The second area of risk comes from the ef&cts of the 
antimicrobial used in the animal on the bacteria present. 
Regardless of the route of administration or the level 
of administration, selection pressure is exerted against 
bacteria in or on some parts of the animal. Most 
documented resistance occurs in animal pathogens 
which are of only passing interest to the medical 
microbiologist as they can only act as donors of 
resistance for man. The bacteria most likely to cause 
direct risk to man are the zoonotic pathogens. These 
include salmonella, campylobacter, verocytotoxic E. 
coli, yersinia, listeria and staphylococci from food and 
contact, and a range of bacteria such as Streptococcus suis, 
Bordetella bronchiseptica, Pasteurella multocida,leptospira sp. 
and Erysipelothrix rhusiopatkiae acquired by contact. 
There is clear evidence that salmonellae, campylobacters 
and yersinias can acquire resistance from antimicrobials 
used in food animals. In the case of salmonella, this may 
have resulted from selection during therapy directed 
against the organism, as salmonellae are capable of 
producing recognizable syndromes in animals and 
treatment is directed against them, but in the case of 
campylobacters, yersinia, E.  coli 0157 and listeria, any 
resistance results from treatment for other organisms 
as these organisms rarely cause recognizable clinical 
syndromes in food animals. 
The two types of resistance are best considered 
in Salmonella enterica and Campylobacter jejuni. S. enterica 
serotype Typhimurium (S .  typhimurium) developed 
multiple resistance in a series of steps in 1964-5 in 
S. typhimtrrium phage type 29 in the UK [7]. This 
resistant strain was shown at the time to carry trans- 
missible resistance and caused widespread infection in 
cattle with some overflow to man to cause both contact 
and food-borne infection. The concern generated by 
this development contributed to the Swann Report [8] 
and to the subsequent Medicines legislation. The organ- 
ism concerned declined in numbers and disappeared 
spontaneously at  the same time as a cattle dealer ceased 
trading. Since then, a similar multiply-resistant S.  
typhimurium, phage type 204, has come [9] and gone, 
and a further resistant S. typhimcrrium, DT104 and 
related strains, has infected cattle and spread to other 
species including man where it has caused life-threat- 
ening infections [10,11]. The resistance in this case is 
chromosomal [lo], so it is not clear whether this strain 
will behave in the same way as the earlier strains. S. 
typhimurium D T  104 carries resistance which indubitably 
arose because of selection during animal treatment, but 
there is no clear evidence as to when this occurred. The 
resistance genes may have arisen prior to the develop- 
ment of multi-resistant D T  104, and the organism has 
certainly spread like an infectious disease along lines of 
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trade within the UK and into countries such as 
Denmark with livestock exports. It can be controlled 
by slaughter and vaccination and does not appear to 
arise de novo. It therefore illustrates that, although 
resistance may originally be selected by the animal use 
of antimicrobials, the organisms themselves can spread 
in the same way as sensitive organisms and do not 
necessarily arise as a result of current veterinary therapy 
although, where multiple resistance is present, selection 
may occur following the use of any of the anti- 
microbials concerned. The factors which give rise to a 
successful clone of this nature and allow it to supplant 
sensitive strains of S. typhimtrrium and then &sappear are 
not yet known and are the subject of intense study. 
The situation with campylobacters is different. In 
food animals therapy has never been directed against 
them. The resistance present to macrolides, tetracyclines 
and to fluoroquinolones has arisen incidentally as a 
result of exposure to antimicrobial used to treat clinical 
disease caused by another agent. This exposure may 
have been as early as the 1960s (macrolide-resistant 
Campylobacter coli were present in pigs in the early 
1970s) and have continued until now, or have arisen as 
recently as this year [12,13]. Fluoroquinolone resistance 
is a case in point. It was not recorded on any scale in 
campylobacters until the introduction of this class of 
antimicrobial for animal therapy. Fluoroquinolones are 
used to treat E. coli septicaemia in young chickens, a 
life-threatening disease in which mortality rates can 
reach lo%, recovered birds grow poorly and following 
which their carcases may be downgraded. It is used in 
other life-threatening diseases of food animals where its 
use is justified from a technical and legal point of view. 
The benefits to the animal may, however, be accom- 
panied by the emergence of fluoroquinolone-resistant 
campylobacters and other elements of thf normal animal 
flora. 
Selection for antimicrobial resistance following 
veterinary antimicrobial use may occur in yersinias and 
frequently does so in staphylococci. Most documented 
antimicrobial resistance occurs in staphylococci in 
milk where the mandatory pasteurization in Scotland 
and other EU countries, and the voluntary pasteur- 
ization in England and Wales, prevent any threat to 
human health. Both raw milk and raw milk products 
such as cheeses can be sources of resistant organisms 
[14]. E. coli 0157 isolates in the UK have not been 
resistant to antimicrobials, but it is clear from other 
countries that multiple antimicrobial resistance can 
occur in this organism. 
Antimicrobial resistance in the normal human flora 
as a result of antimicrobial use in animals has been 
known since the experiments of Williams Smith in 
the 1950s and 1960s [15,16]. His studies showed that 
transient colonization of the human gut with resistant 
E. coli from animals could occur, and that that resistance 
could be transferred to normal human flora in the gut 
where it remained for a variable length of time unless 
selection pressure from antimicrobial occurred, when it 
remained longer [17]. He and other workers demon- 
strated animal E. coli on meat which could act as a 
source of thls resistance for man. In the intervening 30 
years, legislation and codes of practice have eliminated 
the possibility that resistance could arise in E. coli and 
related organisms in animal intestines from the use of 
antimicrobial growth promoters, but have lef? the role 
of therapeutic antimicrobials essentially untouched. 
Antimicrobials registered for use in the EU as growth 
promoters were registered because they were not used 
in animals for therapy in the form used for growth 
promotion, did not affect antimicrobial resistance in E. 
coli and did not conflict with therapy in man in the form 
used at the time of registration. The situation has now 
changed. The identification of antimicrobial-resistant 
enterococci as threats to human health has altered the 
focus of attention from the well-established route of 
transfer of antimicrobial resistance in E. coli &om animal 
feces on undercooked meat to consumers and food 
handlers, to other elements of the animal normal flora, 
namely the enterococci. It has been known for many 
years that the use of the antimicrobial growth promoters 
could select for phenotypic resistance to these anti- 
microbials and other agents in the same class. Little 
attention was paid to this phenomenon until it was 
suggested that vancomycin resistance might be trans- 
ferred kom enterococci to methcillin-resistant Staphylo- 
coccus aureus (MRSA) and render their control in 
hospital infections even more di6cult. Vancomycin- 
resistant enterococci were being selected in the normal 
flora of food animals by the use of avoparcin, a 
glycopeptide growth promoter used widely in chickens 
and pigs in Europe for over 25 years. This class of 
compound is not used in therapy in animals, and the 
gene concerned had not, in fact, transferred to human 
staphylococci in the entire period of use. 
The intense investigations triggered by the realiza- 
tion that vancomycin resistance was present in animal 
enterococci confirmed that the species E. fuecium 
existed in both man and animals, that the resistance 
gene of concern, vunA, was present in animal E. fuecium, 
and that even some flanking sequences could be found 
in both animal and human vanA-resistant enterococci, 
suggesting that there was contact between the two 
populations [18,19]. E. fuecitrm containing uunA was 
found on chicken meat amongst the normal fecal flora 
present as contamination. This work led to the 
suspension of use of avoparcin as a growth promoter in 
the EU, thus effectively ending the controversy, but 
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leaving the focus of attention on the role of anti- 
microbial-resistant enterococci themselves in human 
disease. They have become prominent as causes of 
intractable and sometimes fatal infections in irnmuno- 
compromised patients, and the number of antimicrobials 
to which they are uniformly sensitive is small. Vanco- 
mycin is one such, but vancomycin-resistant entero- 
cocci occur in human infections and, as discussed, may 
have originated in animals or received vanA resistance 
from animal enterococci in the past. Regardless of the 
origin of this resistance, new forms of antimicrobials 
such as streptogramins and everninomycins not pre- 
viously used, or not used on a large scale for human 
medicine, have been developed and are being intro- 
duced or evaluated to deal with these enterococci. 
These two antimicrobials have been used extensively 
for many years for growth promotion in animals as 
virginiamycin and avilamycin, respectively. There is no 
doubt that their use as growth promoters selects for 
resistance to them-selves in animal enterococci, and 
that those enterococci are transferred to man with the 
other elements of the aninial fecal flora on meat. The 
extent to which this results in resistance to either agent 
in human entero-cocci, and particularly those involved 
in human infections, is not yet clear. Preliminary data 
on the susceptibility of enterococci from human 
infections to streptogramins suggests that few are 
currently resistant to these agents even after more than 
20 years of use of the compound as an animal growth 
promoter. When this has been clarified, and factors 
such as the selection pressure exerted by macrolides and 
lincosamides in therapy in animals have been evaluated, 
coherent management strategies can be developed to 
reduce risks to man from these compounds. One such 
strategy is the recent proposal of the E C  to ban the use 
of tylosin, spiramycin (macrolides), virginiamycin 
(streptogramin) and zinc bacitracin from 1999 which, 
if confirmed, will eliminate any risk from these 
substances used in growth promotion. The influence of 
growth promoting anti-microbials on the gut flora has 
been comprehensively reviewed by the Swedish 
Commission on Antimicrobial Feed Additives [20]. 
Effects on human health from antimicrobial therapy in 
companion animals 
Antimicrobial growth promoters are not used in 
companion animals and, with the exception of some 
horses, these species are not used for human con- 
sumption in the EU, so human health cannot be 
affected by the food route. The carnivorous companion 
animals receive sterile canned food or high temperature 
extruded dried foods in most cases and there is little 
contact with food animal bacterial populations unless 
owners feed undercooked or raw table scraps. The 
effects of antimicrobial use are likely to arise directly 
from therapy given to individuals by the parenteral, oral 
and topical routes and risks consist of the direct 
exposure of the owners in a domestic situation to the 
prescribed antimicrobial they administer to their pets 
and contact infections with resistant zoonotic bacteria 
and normal flora from their pets. 
A wider range of antimicrobials is regularly used in 
companion animals than in food animals, and pheno- 
typic resistance to most of those used in companion 
animal therapy has been identified in veterinary 
diagnostic laboratories. The onward transmission ofthis 
resistance from companion animals to the households 
in which they are located is poorly documented. Cases 
ofinfection of members of a household with salmonella 
have been associated with infection in cats, dogs and 
aquarium fish and antimicrobial resistance has been 
identified in salmonellae transmitted to man. In the case 
oftransmission of S. typhimurium DT104 from dogs and 
cats, the pet has often developed clinical disease before 
veterinary treatment has begun and treatment has 
played no  part in its selection. The contribution of 
additional resistance (to fluoroquinolone, for example) 
following veterinary treatment and the importance of 
infection of the household during veterinary treatment 
is not known. Exposure to the feces of infected pets is 
greatest during clinical disease, as the feces of continent 
animals is less frequently handled by the household. 
The situation is different with the infections derived 
from handling fish and tropical reptiles, especially 
terrapins. A wide variety of antimicrobials are used to 
treat and prevent disease in these species in their 
countries of origin, and antimicrobial resistance can 
occur in salmonella derived from recently imported 
animals [21]. Once again, the contribution of any 
veterinary treatment of the animals in Europe has not 
been evaluated. 
Transmission of campylobacters is also possible. 
Although resistance to veterinary therapeutics is not 
uncommonly identified in vitro, resistance to critical 
antimicrobials such as erythromycin is uncommon and 
fluoroquinolone resistance rare in campylobacters from 
UK companion animals at  present. The situation with 
other bacteria is even less clear. Resistance found in 
canine Bordetella bronchiseptica infections to trimethoprim 
sulphonamide has developed as a consequence of 
veterinary use of the antimicrobial, but the importance 
of this has not been assessed formally in infections 
transmitted onward to man. The same applies to Pasteu- 
rella sp. from the canine and feline mouth associated 
with bite wounds in man from those species. Other 
microbial species where the role ofveterinary treatment 
in the onward transmission of antimicrobial-resistant 
organisms or resistance to man is not clear include 
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Staphylococcus intermedius, Pseudomonas aeruginosa, Burk- 
holderia cepacia, Malassezia pachydermatis, and Microsporum 
canis. Enterococci from companion animals are not 
exposed to vancomycin, streptogramins or evernino- 
mycin from veterinary therapy, and veterinary treat- 
ment of pets cannot therefore contribute directly to the 
resistance pool of these antimicrobials in man, but 
enterococci are exposed to gentamicin during therapy 
and may contribute resistance to that substance. In spite 
of the absence of the veterinary use of glycopeptides, 
vancomycin-resistant enterococci have been identified 
in dogs and cats [22]. The source of this resistance and 
its importance is not yet clear. 
Conclusions 
The use of antimicrobials in animals makes a major 
contribution to animal welfare and to the economics of 
farm animal production, with consequent benefits for 
human health. It has also contributed to the emergence 
of antimicrobial resistance in bacteria in animals. There 
are clear examples of the development of resistance in 
zoonotic pathogens such as S. typhimurium following 
historic animal use of antimicrobials, and there is 
evidence with regard to fluoroquinolone resistance in 
campylobacters and salmonellae that this process is 
continuing. The extent to which this resistance is 
associated with human health is clear from the statistics 
related to food-borne infections, where the majority of 
salmonella infection is associated with sensitive strains, 
but the extent to which it is related to current veterinary 
therapy is not clear because of the complicating factor 
of clonal spread and survival of resistant organisms. The 
growth-promoting antimicrobials do not affect resist- 
ance in salmonellae, but do contribute to resistance in 
campylobacters and are responsible for resistance to 
themselves in enterococci. The extent to which this 
impinges on human health is still not clear, but transfer 
of organisms and resistance to man will continue as 
long as animal products remain contaminated with 
animal flora. The part played by veterinary use of 
antimicrobials in companion animals in the transmission 
of antimicrobial-resistant organisms or resistance to 
man has not been fully explored. The animal use of 
antimicrobials does not contribute to the major problems 
of antimicrobial resistance seen in human tuberculosis, 
pneumococcal infection, typhoid or MRSA. Further 
study of the transfer of resistance in animal bacteria to 
man is required in both qualitative and quantitative 
terms. Policies for the management and reduction of 
resistance transfer from animals to man are still being 
formulated. 
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